Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: HIV Infections
Interventions: Tenofovir, Abacavir; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 5
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 2 more

Conditions: Drug Resistance, Multiple, Bacterial, Cholangiopancreatography, Endoscopic Retrograde
Interventions: Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, Microbiome through rectal swab, Microbiome testing duodenal aspirate; Diagnostic Test
Lead sponsor: Marco J. Bruno; Other
Eligibility: 18 Years and older
Enrollment: 1,244 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Seizures
Interventions: Placebo, CVL-865; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 37
States / cities: Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more

Conditions: Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions: Ciforadenant, Ciforadenant + atezolizumab; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Tucson, Arizona • San Francisco, California • Stanford, California + 11 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Conditions: Non-Small Cell Lung Cancer
Interventions: KAN-001, Pembrolizumab; Biological
Lead sponsor: Kanvas Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Maumee, Ohio

Conditions: Pneumonia, Blood Stream Infection
Interventions: colistin and meropenem, colistin and placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 95 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Detroit, Michigan • Royal Oak, Michigan + 2 more

Conditions: Seizures
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions: BLU-222, Carboplatin, Ribociclib, Fulvestrant; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more

Conditions: Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions: CNTO 328; Anti-interleukin-6 monoclonal antibody; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: MRSA
Interventions: Retapamulin, Placebo Ointment; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 9 Months to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: spironolactone, amiloride; Drug
Lead sponsor: VA Salt Lake City Health Care System; Federal
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Herpes Simplex, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epilepsy, Seizures, Drug Resistant Epilepsy
Interventions: Vagus Nerve Stimulation (VNS) Therapy; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 19
States / cities: Grand Junction, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 15 more

Conditions: Adrenal Cortical Carcinoma
Interventions: doxorubicin, vincristine, and etoposide with mitotane; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions: APL-1202; Drug
Lead sponsor: Asieris Pharmaceutical Technologies Co., Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Myrtle Beach, South Carolina

Conditions: Prostate Neoplasms
Interventions: Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide, Theophylline; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Beverly Hills, California • San Antonio, Texas

Conditions: Epilepsy Intractable
Interventions: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: exenatide, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon

Conditions: Aging, Aging Well, All-Cause Mortality, Mortality, Metabolic Syndrome, Cardiovascular Diseases, Cognitive Dysfunction, Musculoskeletal Diseases, Neoplasms, Frailty, Activities of Daily Living, Health-Related Quality of Life, Disability Physical, Neuro-Degenerative Disease, Dementia
Interventions: Comprehensive Multi-System Clinical Screening; Diagnostic Test
Lead sponsor: Longevity Metrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2099
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Drug-resistant Focal Seizure
Interventions: OnabotulinumtoxinA 145 UNT [Botox]; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin's Disease, Non Hodgkin's Lymphoma
Interventions: PBSC, IL-2, EPOCH II; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more

Search by objective public record fields.

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Identifying Diuretic Resistance in Patients With Acute Heart Failure

(VELA) Study of BLU-222 in Advanced Solid Tumors

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Retapamulin as a Decolonizing Agent for MRSA

Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Neuronal Mechanisms of Human Episodic Memory

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

100-Year Human Aging Study

BOTOX Effects on Seizure Severity and Susceptibility

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen